We are indebted to the Upjohn Company and to the William Warner Company for the heparin employed in this study. Brand A (Plain): heparin sodium, 200 mg.; sodium ethyl mercuri thiosalicylate, 0.1 mg.; gelatin, 18%; dextrose, 8%; glacial acetic acid to l)H 5.6; double distilled water q.s.a.d., 1 ml. Brand A (Vasoconsl ictor): heparin sodium, 200 mg.; sodium ethyl mercuri thiosalicylate, 0.1 mg.; gelatin, 18%; dextrose, 8%; ephedrine HCl, 10 mg.; epinephrine HC1, 1 mg.; glacial acetic acid to pH 5.6; double distilled water q.s.a.d., 1 ml. Brand B (Plain): heparin sodium salt, 200 mg.; (.hlorabutinol, 0.5 mg.; eucupin (lihydrochloride 1 mg.; Pitkin's menstruum 2 ml. Brand B (Vasoconstrictor): heparin sodium salt, 530
Heparin/Pitkin menstruum has been advocated in the therapy of a variety of thromboembolic disorders. The clinical properties of two such mixtures each with and without vasoconstrictor agents is evaluated and it is demonstrated that a significant prolongation of the clotting time beyond 24 hours cannot be obtained. A comparison between the one tube and the three tube methods for the determination of the coagulation time of blood reveals that both procedures yield comparable data. R ECENT REPORTS have indicated that a Pitkin heparin menstruum can produce a consistent prolongation of the clotting time for as long as 48 hours.'-3 During the course of studies on the effectiveness of this mixture in the therapy of myocardial infarction, we found that the duration and uniformity of action were less than that reported by others.6 Consequently, it became necessary to reevaluate the properties of this mixture in terms of the onset and extent of its effect on blood coagulation, as well as the duration of this action.
METHOD
Two commercially available brands* of heparin in retarding media were utilized in the present study. Aided in part by a grant from the U1pjohn Coinpiany.
Brand A contained 200 mg. of the sodium salt of heparin per ml. while Brand B contained 100 mg. of the same salt per ml. Unless otherwise noted, each subject was given a single injection of an amount of menstruum which contained 400 mg. of heparin, i.e., subjects given Brand A received 2 ml. of the mixture while those given Brand B received 4 ml. of the mixture. The heparin was deposited into the deep subcutaneous tissues in the upper quadrant of the buttock through a 20 gage needle. W, 'hen the injection was given, the needle was rotated so as to insure equal distribution of the menstruum.
The coagulability of the blood was determined by means of clotting times estimated by a modification of the Lee-White method. For this purpose, venepuncture was performed with a dry, sterile, 20 gage needle and a 5 ml. syringe. Two ml. of blood were withdrawn without the introduction of air into the syringe. If the vein was not cleanly negotiated, the sample was discarded. The needle was removed from-the syringe, 1 ml. of blood gently expressed from the syringe and allowed to run down the side of a dry, clean test tube measuring 13 by 100 ml. The tube was then gently tilted to an angle of 90 degrees once every minute until the blood no longer ran down the side of the tube. Thereafter, the tube was progressively tilted once every minute until, at 180 degrees, Imo motion of the blood was noted. This was arbitrarily taken as the end point of the clotting process. The clotting time with this one tube procedure was 8.9 minutes (S.D. = ±2.2) for a group of 76 subjects.
To determine the validity of the one tube method as outlined above, 7 coagulograms were made on the bloods of 4 patients, using a three tube method similar to that outlined by Gradwohl7 and by Loewe and Eiber.3 One ml. of blood was expressed from the syringe into each of three test tubes. Clotting in the H. I. GIUECK, C. J. PODORE, AND J. E. LEVINSON first tube was determined by the method described above. One minute after obtaining the end point in the first tube, the second tube was similarly treated and thereafter the coagulability of the blood in the third tube was determined.
The subjects selected for study consisted of patients in whom there were no evidences of thromboembolic disease, heart disease, carcinoma, infections or recent operations. The subjects so selected were studied in groups designed to reveal the influence of b)e(l rest and of the presence of a vasoconstrictor ill the menstruum on the time of onset of action andlduration of effect of the administration .of two brands of heparin in retarding media.
RESULTS
The clotting time as measured by the one, two and three tube procedures was determined in 4 subjects who received 7 separate injections of 400 mg. of Brand A heparin. The coagulograms thus obtained consisted of three parallel curves at each interval, when they were expressed in terms of the absolute (letting time. The clotting time obtained by the three tube method was greater than that obtained with the use of two tubes, while that derived by the one tube method always gave the shortest clotting time. This relationship was found to be true for the pre-injection (lotting times of blood as well as for those blood samples drawn after the injection of heparin. XWhen the data were expressed as the per cent change from the pre-injection clotting times, essentially similar results were obtained by the uise of one, t wo or three tubes. An analysis of variance& revealed that the differences between data obtained by the pro-(edure usting one, two or three tubes as outlined above were not significant at any of the intervals. The apparently greater effect noted ait 6 hours with the one tube method could not be distinguished statistically from that obtained by use of the other two tubes. Therefore, any of the three tubes yields comparable information in regard to the percentage increase in clotting time during heparin therapy. This point is of some practical importance sintce it validates the use of the one tube proe(lure and thus decreases the absolute time re(luired for a determination of the clotting time of blood ( fig. 1 ). A total of 82 coagulograms were obtained from 76 subjects. The data obtained after various treatments are summarized in table 1. In order to determine the effect of bed rest or activity on the action of heparin in retarding media, Brand A heparin without vasoconstrictor was administered to ambulatory subjects (group 1) and to patients confined to bed for the purposes of this study (group 2). The 17 coagulograms on the ambulatory subjects and 20 coagulograms on the subjects at bed rest are essentially the same (table 1) . Since no statistically significant difference could be demonstrated between the data obtained from both groups at various intervals, it may be anticipated that the use of repository heparin in ambulatory patients will yield data similar to that obtained in patients who are immobilized and confined to bed. 119
In order to compare the two brands of heparin, coagulograms obtained after the administration of Brand A (group 2) were compared with the data obtained from subjects injected with Brand B (group 3). Twelve of the 14 subjects in group 3 were also utilized to determine the effect of Brand A. The administration of Brand B preceded the administration of Brand A by at least 48 hours in six of these subjects, while the administration of Brand B followed the administration of Brand A by at least 48 hours in the others. An analysis of the data obtained in this manner revealed that the two brands are essentially similar in their effect on the prolongation of clotting times. When z either brand of heparin was administered, 'a rapid and progressive increase in the clotting time was noted which by the end of four hours was three times that of the pre-injection level. The peak of the heparin effect was reached 6 hours after injection. From 18 to 20 hours after the injections the clotting time of the blood remained between two to four times that before the injection of heparin. Thereafter, a progressive decline in clotting time occurred so that by the end of 24 hours after the injection of either Brand A or B, there was no statistically significant deviation from the pre-injection clotting time.
Of interest is the fact that five of the 20 subjects who received Brand A complained of pain at the site of the injection; 2 of these developed hematomata. Eight of the 14 patients receiving Brand B complained of local pain; one of these developed a hematoma.
In order to determine the effect of the inclusion of a vasoconstrictor in the menstruum, coagulograms were obtained on patients injected with Brand A containing vasoconstrictor (group 4) and on patients injected with Brand B containing vasoconstrictor (group 5). In eight instances, the same subjects were utilized to test the action of the two brands and in such instances, at least 48 hours intervened between injections.
The data summarized in table 1 reveal that the action of the two brands containing vasoconstrictor is essentially similar. Although the increase in clotting time appeared to occur at a more rapid rate with Brand A than with Brand B, students' "tC test' showed that the difference between the effect of the two brands is insignificant. Twenty-four hours after the injection of both brands, the clotting time was approximately two and one-half times greater than the initial time, but by 30 hours after the injections the clotting time had approached the pre-injection clotting times in both groups. Five of the 17 patients injected with Brand A complained of pain as did also 2 of the 9 patients injected with Brand B. No significant alterations in the blood pressure or heart rates were noted during the performance of the tests.
The incorporation of a vasoconstrictor agent in the menstruum definitely prolongs the dura-tion of the decreased coagulability of the blood as compared with the effect of a similar preparation of heparin containing no vasoconstrictor agent ( fig. 2) . It is evident, however, that the decreased coagulability of the blood does not reach the so-called therapeutic levels as rapidly as does the heparin menstruum containing no vasoconstrictors. Consequently, despite the apparent increase in the duration of the effect induced by heparin containing vasoconstrictors, the actual duration of a therapeutically effective hypocoagulability is not maintained for more than 16 hours.
It has been suggested that an effective prolongation of the clotting times may be attained by simultaneous injection of two types of heparin mixtures, i.e., of a heparin mixture with, and one without, vasoconstrictor.-1 Accordingly, we tested this hypothesis by administering an injection of 200 mg. of Brand A without vasoconstrictor in one buttock and a simultaneous injection of 200 mg. of Brand A with vasoconstrictor in the other buttock of each of five subjects (group 6). The coagulability of the blood was determined at four-hourly intervals after the injections. A significant prolongation of the clotting time was first noted 8 hours after injection; this persisted for 28 hours and began to approach the pre-injection coagulability by the end of 32 hours (table 1) . 0 EFFICIENCY OF HEPAIRIN lt is evident from figure 2 that before the eighth hour after injection there was very little difference between the action of the mixture of heparin with and without vasoconstrictor agents on the one hand (group 6) and that of the heparin containing only vasoconstrictors (group 4) on the other. At the twentieth hour after injection, the prolongation produced in group 6 is somewhat greater than that in group 4 but thereafter the differences are not statistically significant.
DIscussIoN
The responses of a group of subjects to any pharmacologic agent will tend to fall along a normal distribution (urve. For that reason, fluctuations in the degree of effect of the same type of heparin were anticipated and, as a matter of fact, were noted from patient to patient. The mean responses of the groups, however, represent the type of result that can be expeeted from the administration of the sevetal types of heparin to large groups of subjects.
These studies (1o not confirm the contention that an effective decrease in the (.oagulab)ility of the blood for from 36 to 48 hours results from the single injection of a heparin menstruum.'-Further, the incorporation of vasoeonst rict or aogents in the menstruum mer elyl delavs the onset of the effect and (lees not prolong the luration of the therapeutically effective de-(tease in the coagulation of the bloodl (fig. 2 ).
Since the administration of repository heparin results in a relatively rapid decrease in the coaglulability of the blood while the action of heparin mixtures containing vasoconstrictors results in a prolongation of the effect once it appears, it wvas postulated that the simultaneous administration of these two mixtures of hieparin might prove more effective than the injection of either alone. The data obtained with group 6 reveal that the above does not ose(ur. Whether the failure to obtain a rapid levelopment of the heparin effect was (lue to the use of only one-half the quantity of plain heparin in retarding medium was not deterinin.d. The lack of any evidences of a systemic effect of the vasoconstrictors makes it improbable that such an effect played a role in delay-ing the rate at which the heparin was absorbed from the contralateral side.
Loewe and his associates have postulated' that patients with thrombophlebitis usually require only 300 mg. of a mixture of plain heparin and that containing vasoconstrictors, whereas those with coronary thrombosis usually require 400 mg. of the preparation without vasoconstrictor in order to maintain effective therapeutic levels. For such reasons we employed the higher dosage of heparin in the present study. Consequently, the discrepancy between the data reported herein and those of Loewe cannot be attributed to an insufficient dosage. Since we found no essential differences between the two commercially available brands of heparin, the discrepancy cannot be attributed to differences in the composition of the menstruums.
It would appear from our data that to maintain an effective diminution of the coagulalbility of the blocd, injections of heparin in retarding media should be made at more frequent intervals than 32 to 48 hours. Such a conclusion is inherent in the recent studies of )e'l'akats' who utilized a different method to measure the coagulability of the blood and obtained dlata essentially similar to that reported herein.
SUMMARY AND CONCLUSIONS 1. Estimation of the clotting time of the blood by means of either the one tube or three tube procedure yields values which are comparable when the clotting time is expressed in terms of the percentage increase above the initial level.
2. The effect of heparin in retarding media is not influenced by bed rest since similar changes in the coagulability of the blood are induced in subjects who are ambulatory as well as those confined to bed.
3. Evidence could not be obtained that the single injection of various types of heparin in retarding media is effective in maintaining a decreased coagulability of the blood for more than a twenty-four hour interval.
